Staidson Biopharma ^Company

Staidson Biopharma is a early stage therapeutic drug discovery company, dedicated to discovering the next generation of medicines for the treatment of various human diseases. Chinese authorities approved clinical trials of IFX-1, a Staidson Biopharma`s development, as a COVID-19 treatment in February. The company however has not listed IFX-1 as a COVID-19 treatment, only stating it is in additional development for “undisclosed chronic inflammatory and autoimmune diseases,” according to a presentation at the SVB Leerink Global Healthcare Conference, held February 25–27.